FWBI - First Wave BioPharma, Inc. Stock Price, Fair Value and News

$0.99-0.04 (-3.88%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FWBI Price Action

Last 7 days

1.9%

Last 30 days

-47.3%

Last 90 days

-67.2%

Trailing 12 Months

20.4%

FWBI RSI Chart

FWBI Valuation

Market Cap

5.2M

Price/Earnings (Trailing)

-0.52

EV/EBITDA

-0.27

Price/Free Cashflow

-0.42

MarketCap/EBT

-0.29

FWBI Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FWBI Fundamentals

FWBI Earnings

Earnings (TTM)

-9.9M

Earnings Growth (Yr)

24.84%

Earnings Growth (Qtr)

70.7%

FWBI Profitability

Return on Equity

-118.56%

Return on Assets

-11.56%

Free Cashflow Yield

-240.95%

FWBI Investor Care

Shares Dilution (1Y)

604.30%

Diluted EPS (TTM)

21.44

Revenue & Growth

About First Wave BioPharma, Inc.

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

CEO	Mr. James R. Sapirstein M.B.A., R.Ph.
WEBSITE	firstwavebio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	10

First Wave BioPharma, Inc. Frequently Asked Questions

What is the ticker symbol for First Wave BioPharma, Inc.? What does FWBI stand for in stocks?

FWBI is the stock ticker symbol of First Wave BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of First Wave BioPharma, Inc. (FWBI)?

As of Thu Oct 31 2024, market cap of First Wave BioPharma, Inc. is 5.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FWBI stock?

You can check FWBI's fair value in chart for subscribers.

Is First Wave BioPharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether FWBI is over valued or under valued. Whether First Wave BioPharma, Inc. is cheap or expensive depends on the assumptions which impact First Wave BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FWBI.